An anti-VEGF designed ankyrin repeat protein (DARPin) has been successfully used in AMD models,17 and it is now being evaluated in clinical trials
An anti-VEGF designed ankyrin repeat protein (DARPin) has been successfully used in AMD models,17 and it is now being evaluated in clinical trials.18 In addition, an ODM-203 alternative class of antibodies, the camelid-derived nanobodies are in several trials (e.g., anti-IL-6R for autoimmune diseases19). lack the Fc domain name, as a safer alternative. To investigate the feasibility of this, anti-vascular endothelial growth factor (VEGF)-blocking antibodies in two formats were produced and tested and compared to larger standard antibodies, 16 thus acting on a greater area of the retina. An anti-VEGF designed ankyrin repeat protein (DARPin) has been successfully used in AMD models,17 and it is now being evaluated in clinical trials.18 In addition, an alternative class of antibodies, the camelid-derived nanobodies are in several trials (e.g., anti-IL-6R for autoimmune diseases19). However,…